Michael Latwis

RealMoney.com Contributor

Michael Latwis directed health care content at TheStreet.com Professional Products. He also has worked at Barclays Wealth management division and was previously associated with Lazard Freres and Fiduciary Trust. Latwis covered companies in the pharmaceutical and specialty pharmaceutical sectors as well as biotech, medical technology, healthcare services, retail and media stocks. He has an MBA from Pace University.

Michael Latwis
By This Author:
Page 2 of 7
Article

Deal Could Transform Kyphon (RealMoney.com $)

By Michael Latwis

The medical-device maker's acquisition sends shares soaring.

10:46AM 12/08/06

Article

Abbott Labs Is Positioned for Improved Growth

By Michael Latwis

Opportunities include stents, Humira, diabetic treatments, and cholesterol drugs.

09:50AM 12/05/06

Article

Pfizer's Worst-Case Scenario

By Michael Latwis

The latest surprising setback may lead to some strategic reverberations.

07:50AM 12/05/06

Article

Pfizer's Worst-Case Scenario (RealMoney.com $)

By Michael Latwis

The setback may lead to some strategic reverberations.

02:04PM 12/04/06

Article

Expectations Deflated for Alkermes

By Michael Latwis

The company's alcohol-treatment drug did not have the expected impact.

03:17PM 12/01/06

Article

Expectations Deflated for Alkermes (RealMoney.com $)

By Michael Latwis

The company's alcohol-treatment drug did not have the expected impact.

10:29AM 12/01/06

Article

Defibrillator Boost May Recharge Greatbatch (RealMoney.com $)

By Michael Latwis

A rebound in defibrillators is good for this small-cap.

10:07AM 11/29/06

Article

J&J's Conor Buy Props Up Its Lead (RealMoney.com $)

By Michael Latwis

The deal is a smart move to stay a major player in the drug-eluting device market.

08:18AM 11/21/06

Article

Shop Carefully for Generic-Drug Makers (RealMoney.com $)

By Michael Latwis

Their stocks have fallen, but there's good reason for the lower prices. Still, two players offer promise.

10:45AM 11/15/06

Article

Dendreon's Risks Will Yield Rewards

By Michael Latwis

The biotech firm's bold strategy with the FDA on its cancer vaccine is likely to pay off.

07:42AM 11/15/06

Page 2 of 7
Dow Jones S&P 500 NASDAQ 10-Year Note
10,471.58 1,108.86 2,175.81 32.75
Oil *
79.69
UP
126.74
UP
13.23
UP
31.21
UP
0.74
10 Yr
3.28%
SPDR Gold
117.38
+1.23%
+1.21%
+1.46%
+2.31%
Data delayed 20 minutes

Brokerage Partners